The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Livedataaccount, does it? what are they? I've not seen a new strategy every meeting.
Did you listen to the Wednesday interview?
Touk, regarding the below, I could have sworn that you had the persona of a naive investor who was hoping against hope that this would come off, as it was a decent portion of a pension pot or something. Rather than a 'better place to put the money right now' or is that a slip up?
Toukankahmoon
Posts: 1,759
Price: 53.00
No Opinion
RE: Going forwardToday 08:54
Agree with analysis but don’t see this as a buy quite yet because better place to put money for returns over next few months
Regarding Phase 3, there has to be a phase 3 either ongoing or planned at the point that phase 2 is used as registrational, so it should not add to the timeline, it can be in this case a post approval activity.
24 mins in: https://www.youtube.com/watch?v=eqj0hhgmX6U
And the whole purpose of this study is to find DLTs, note that not enough/not strong enough DLTs have been found to stop dosing faster or higher, as some of these were not in the final cohort.
Not being Juvenile Touk, just not mincing words, calling you out for what you are. I think you add little value from the posts i've seen, in fact you detract from it. So your opinion is irrelevant to me. PL75 adds value, so I speak differently to him, the message might not be what he wants to hear, but that's a different issue.
again touk, you prove my point. i've not once said search for it. and frankly i don't give two ****s what wyn says, he is solely here to be disruptive, why would anyone want him in a group, again it's not balance if the sole intent is to disrupt, which it is.
PL75, honestly, it's the responses here, and the last time, that make me (and it's not my decision by any means) not want to share them. But it doesn't actually matter, the purpose was to seed some questions that aren't 'how does it work', some interesting questions that haven't been approached before but should have been, the questions will be seen on the day, those that they are allowed to answer at least.
In fact if you all ask the same questions that probably tells Avacta more about what LTHs are looking for from them than if you self-censor and don't even ask the question because you know it's already been asked. Sure it'll cost them some time collating them, but knowing that there are say 10 wholly independent people all wanting to know the same thing is important in my opinion.
Meanwhile some can ask is it ribena coloured, and which flavour is it?
What point does that prove? I think you may have just proven my point that you are moronic. You try to counter 'ramping' that you can't actually find, and instead are solely negative, that not balance that's just being negative, not realistic, negative. What could you bring to the group, what could you add?
strangy, there is nothing, absolutely nothing stopping you from emailing any ceo, whether they respond is up to them, they might weigh up holding size, and tone of the questions before responding, but that's their choice. many ceo's don't respond at all. so it's not 'not right' it's just that you can't be bothered to do it yourself, and gathering a group together here is pointless. just like that twazzock the other week that wanted to 'see the lab' as if that would give some kind of proof, if i were a ceo i'd not bother responding to that. so get off your **** and stop expecting things to be handed you on a plate if you are not going to get involved.
my vote on that group is to share nothing here. not even that the questions are being asked.
What are you going to learn, they have a good stock of white coats that look nice and clean, the coffee is good but not too good, likewise with canteen, the cars in the carpark are acceptable, they are moving liquids and some solids around, can't really tell it's in a lab and you're on the wrong side of the glass. What are you going to achieve?
Don't be soft. Who'd go, all of us? no one would ever be satisfied with who went, ophidian would have a hissy fit a dox people if he didn't, and he'd them they were doing it wrong if he did. Think about the practicalities of what you just asked.
Yes more revenue, possibly less cost per standard dose period as you're not dealing with side effects as well, with all of their specialties and drugs. But one of the reasons that the dox has a limited revenue per patient is that they die.
Interesting, would be a nice surprise, but I'm putting it in the unlikely to happen box. If we were BP probably more likely to happen.
What is 'a pill' a pill of what? There are chemo's available in pill form...
Did he? I don't recall that. Any evidence?
New retail can buy new retail levels of volumes at the current price which is 4% above placing, so that's not really a problem is it, and lets face it traders are far far more likely to sell on at the first rise than an Insti who will generally hold for longer as they will have approval processes to buy & sell with target prices etc. vs a trader who 'just reacts'.
You don't remember correctly, both were present, doing different jobs.
I can't help looking at winnie on occassions, and to answer one of his pointless points.
What's the very very very worst case scenario for cohort 7 data in a safety trial. They are seeing side effects? So the limit has been found, which was the point, and they drop the dosage to cohort 6 levels, still well above straight dox. That's the worst case scenario, even if the side effects are lethal.
Technically everyone on the planet is required to rule out rare and idiosyncratic reactions.